Abstract P6-11-12: A Novel Capecitabine Schedule (7 on — 7 off) Is Feasible with Lapatinib for Patients with HER2-Positive Metastatic Breast Cancer Refractory to Trastuzumab

MLA

Diana Lake, et al. “Abstract P6-11-12: A Novel Capecitabine Schedule (7 on — 7 off) Is Feasible with Lapatinib for Patients with HER2-Positive Metastatic Breast Cancer Refractory to Trastuzumab.” Cancer Research, vol. 70, Dec. 2010, pp. P6-11. EBSCOhost, https://doi.org/10.1158/0008-5472.sabcs10-p6-11-12.

APA

Diana Lake, Maria Theodoulou, Devika Gajria, Larry Norton, S. Geneus, Ta. Traina, Clifford A. Hudis, S. Patil, Kimberly Feigin, Gabriella D’Andrea, & Pamela Drullinsky. (2010). Abstract P6-11-12: A Novel Capecitabine Schedule (7 on — 7 off) Is Feasible with Lapatinib for Patients with HER2-Positive Metastatic Breast Cancer Refractory to Trastuzumab. Cancer Research, 70, P6-11. https://doi.org/10.1158/0008-5472.sabcs10-p6-11-12

Chicago

Diana Lake, Maria Theodoulou, Devika Gajria, Larry Norton, S. Geneus, Ta. Traina, Clifford A. Hudis, et al. 2010. “Abstract P6-11-12: A Novel Capecitabine Schedule (7 on — 7 off) Is Feasible with Lapatinib for Patients with HER2-Positive Metastatic Breast Cancer Refractory to Trastuzumab.” Cancer Research 70 (December): P6-11. doi:10.1158/0008-5472.sabcs10-p6-11-12.